Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Patents (Class 514/165)
  • Patent number: 11891451
    Abstract: The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 6, 2024
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico Callewaert, Bram Laukens, Loes Van Schie, Wander Van Breedam, Wim Nerinckx
  • Patent number: 11793800
    Abstract: The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: October 24, 2023
    Assignee: SEN-JAM PHARMACEUTICAL INC.
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl
  • Patent number: 11723864
    Abstract: The claimed invention is directed to the use of a composition for use as an antimicrobial comprising an antimicrobial agent. In certain embodiments, the composition is used for treating or ameliorating inflammation in a subject and comprises an anti-inflammatory agent. The anti-inflammatory agent may include an NSAID, such as ibuprofen or diclofenac. The composition may further include solvents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents, anti-viral agents, and buffers. The composition may include particles that have been processed via jet milling to reduce a diameter of the particles and to improve a flowability of the particles.
    Type: Grant
    Filed: May 29, 2016
    Date of Patent: August 15, 2023
    Assignees: The Texas A&M University System, The Board of Regents of the University of Texas System
    Inventors: Carolyn L. Cannon, Parth N. Shah, Justin A. Smolen, Hugh D. Smyth, Ashkan K. Yazdi, Matthew J. Herpin
  • Patent number: 11622937
    Abstract: The subject invention relates to compositions of a polyphenolic Polymer and methods useful for the delivery of substantially water-insoluble drugs and agrochemicals, like Artemisinin, Aspirin, and Pyrethrin. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary polyphenolic partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary polyphenol molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: April 11, 2023
    Inventor: Mewa Singh
  • Patent number: 11564957
    Abstract: The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: January 31, 2023
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Patent number: 11510894
    Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: November 29, 2022
    Inventors: John P. Geibel, Philipp Kirchhoff
  • Patent number: 11453840
    Abstract: A method of applying energy to CBD oil is provided. The method may include obtaining CBD oil from a plant, combining the CBD oil with a carrier oil, heating the combination of the CBD oil and carrier oil, mixing the CBD oil and carrier oil, filtering the CBD oil and carrier oil to a size of less than 60 nanometers, and applying an energy field to the CBD oil and carrier oil through a laser effector such that an electron is promoted from a bonding or non-bonding orbital into an empty anti-bonding orbitals of the CBD molecule. The laser effector may be a pink sapphire cut into a 15 equal side faceted crystal, double-stacked in a 2.3 cm cylindrical chamber, or an opulence half dome bubble lens configured to refract the beam.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: September 27, 2022
    Inventor: John Anton Broadhurst
  • Patent number: 11331295
    Abstract: Methods of using a high-dose statin for treatment of AMD in a patient can be used to regress drusen and/or drusenoid pigment epithelial detachments (PEDs), to prevent atrophy of the RPE and/or one or more photoreceptors, to prevent vision loss and/or improve visual acuity, and/or to prevent progression from dry AMD to wet AMD.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 17, 2022
    Assignee: MASSACHUSETTS EYE AND EAR INFIRMARY
    Inventors: Demetrios Vavvas, Joan W Miller
  • Patent number: 11273194
    Abstract: The present invention relates to a pharmaceutical composition containing an avocado oil fraction as an active ingredient for prevention or treatment of hearing loss. Specifically, the avocado oil fraction according to the present invention, especially, an isopropanol fraction of avocado oil significantly increases the number of hair cells reduced by neomycin in zebrafish models, so the isopropanol fraction of avocado oil can be favorably used in the treatment of hearing loss.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: March 15, 2022
    Assignee: DONG KOOK PHARM CO., LTD
    Inventors: Bin Na Hong, Woo Jae Jung, Kye Wan Lee, Jung Suk Lee, Yu Hwa Park, Do Hoon Kim
  • Patent number: 11135153
    Abstract: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 5, 2021
    Assignee: TECHFIELDS PHARMA CO., LTD.
    Inventors: Chongxi Yu, Lina Xu
  • Patent number: 11112402
    Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: September 7, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Mayur Movalia, Andrea Illingworth, Susan Faas McKnight, Russell P. Rother
  • Patent number: 11103472
    Abstract: The present specification discloses pharmaceutical compositions formulated as a suspension for oral administration, the suspension comprising solid particles of a non-steroidal anti-inflammatory drug (NSAID) in an oil carrier comprising one or more free fatty acids, a glycerolipid, and a phospholipid as well as methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: August 31, 2021
    Assignee: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Wilson Caparros-Wanderley, Gregory Alan Stoloff, Suzanne Jane Dilly, Gemma Szucs, Olga Pleguezuelos Mateo
  • Patent number: 11077080
    Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: August 3, 2021
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE AUX ENERGIES ALTERNATIVES, BIO MODELING SYSTEMS OU BMSYSTEMS
    Inventors: Franck Mouthon, Mathieu Charveriat, Jean-Philippe Deslys, François Iris
  • Patent number: 11045436
    Abstract: This invention discloses uses for sulindac in preparing anti-lung cancer products. This invention provides uses for sulindac in the preparation of products to treat lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug sulindac, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that sulindac has a new use as an anti-lung cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: June 29, 2021
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Patent number: 10874653
    Abstract: The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Sen-Jam Pharmaceutical LLC
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl
  • Patent number: 10857106
    Abstract: Methods for treating and/or delaying onset of dysplastic lesions in the bronchial airway of an individual comprise delivering to the respiratory track of the individual an inhalable dry powder composition including an effective amount of myo-inositol.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: December 8, 2020
    Assignees: The Regents of the University of Colorado, a Body Corporate, Aktiv-Dry LLC
    Inventors: Robert E. Sievers, Stephen Cape, David McAdams, J'aime Manion, Pankaj Pathak
  • Patent number: 10828286
    Abstract: In some embodiments, the present disclosure pertains to a composition including niacin up to about 1000 mg and berberine up to about 800 mg. In some embodiments, the niacin is in an amount of about 500 mg and the berberine is in an amount of about 100 mg. In some embodiments, the present disclosure pertains to a method that includes administering a composition to a subject in need thereof, where the composition includes niacin up to about 1000 mg and berberine up to about 800 mg. In some embodiments, the niacin is in an amount of about 500 mg and the berberine is in an amount of about 100 mg.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: November 10, 2020
    Assignee: GM Pharmaceuticals, Inc.
    Inventor: Odes W. Mitchell
  • Patent number: 10695309
    Abstract: Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 30, 2020
    Assignee: WESTERN NEW ENGLAND UNIVERSITY
    Inventors: Shabnam N. Sani, Hamid Bakhteyar
  • Patent number: 10568858
    Abstract: The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: February 25, 2020
    Assignee: SOLUTEX NA LLC
    Inventors: Gerhardus Lucas Bannenberg, Charles Nicholas Serhan, Fernando Moreno Egea
  • Patent number: 10456469
    Abstract: The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 29, 2019
    Assignee: SERBIG PHARMACEUTICALS CORP.
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Patent number: 10391096
    Abstract: A method for treating thrombotic disorders using a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid. Also disclosed is a method of improving the efficacy of a blood thinning medication by co-administering a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid to a subject being treated with a blood thinning medication.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: August 27, 2019
    Assignee: Quercegen Pharmaceuticals LLC
    Inventor: Thomas Christian Lines
  • Patent number: 10391080
    Abstract: Methods of treating cancer, including PAR-4 implicated cancers or renal cell carcinoma, using ketorolac are disclosed herein. Ketorolac can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 27, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10238622
    Abstract: The invention provides methods of treatment that prevent the onset of Mesial temporal lobe epilepsy (TLE) in a subject, or which reduce the severity of TLE in a subject, by administering a NKCC1 inhibitor to the subject after the subject has suffered from an insult known to precipitate TLE.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: March 26, 2019
    Inventors: Wolfgang S. Mueller, John A. Connor, Steven Peterson, Denis Bragin
  • Patent number: 10124005
    Abstract: Migraine is a multi-symptom disease involving pain; histamine triggers; and nausea with or without vomiting. Current over-the-counter medications focus only on treating pain. This invention involves treating other common triggers and symptoms as well as pain. Acetaminophen and caffeine are already being used but the addition of meclizine is what makes this medication my invention. The addition of meclizine covers the other symptoms that make migraine sufferers miserable which is nausea/vomiting and treats the possible histamine mediated trigger of migraines because it has antihistaminic properties. As a migraine sufferer myself, I experience all of these symptoms and would very much like to have everything I need to cover these debilitating symptoms in one medication hence my invention.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: November 13, 2018
    Inventor: Lisa Josette Myslinski
  • Patent number: 10103225
    Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: October 16, 2018
    Inventors: Michelle Reillo, Marian E. Washington
  • Patent number: 10084044
    Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 25, 2018
    Inventors: Michelle Reillo, Marian E. Washington
  • Patent number: 10000735
    Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiating an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell, produced by using the medium composition into a neuron. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into neurons.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: June 19, 2018
    Assignee: BBHC CO., LTD.
    Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
  • Patent number: 9974763
    Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: May 22, 2018
    Assignees: B&A THERAPEUTICS, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AUX MARSEILLE, UNIVERSITE DE NANTES
    Inventors: Yehezkel Ben-Ari, Nathalie Dehorter, Philippe Damier, Constance Hammond
  • Patent number: 9956187
    Abstract: The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 1, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Renyu Liu, Geoffrey Krug, Feixiang Wu, Julie Blendy
  • Patent number: 9896411
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2018
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9839612
    Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 12, 2017
    Inventors: Michelle Reillo, Marian E. Washington
  • Patent number: 9750725
    Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Ra?, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 5, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 9676715
    Abstract: Novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITE JOSEPH FOURIER
    Inventors: Jean-Noël Denis, Marcelle Claude Jolivalt, Louis Maurin Max Maurin, Matthieu Jeanty
  • Patent number: 9351980
    Abstract: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 31, 2016
    Assignee: The University of Wolverhampton
    Inventors: Christopher John Perry, Iain Douglas Nicholl
  • Patent number: 9345678
    Abstract: Embodiments described herein are directed to prostanoid (IP) receptor agonist compounds, including cicaprost and certain prodrugs, and methods of preparation and use for the same. Certain embodiments are directed to the use of cicaprost and certain prodrugs in the treatment of topical and ocular conditions.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 24, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Jenny W. Wang, David F. Woodward, Neil J. Poloso, Julia Herrmann
  • Patent number: 9321785
    Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: April 26, 2016
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Nellithanath Thankachen Byju
  • Patent number: 9308211
    Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
    Type: Grant
    Filed: May 24, 2014
    Date of Patent: April 12, 2016
    Assignee: Infirst Healthcare Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 9289439
    Abstract: A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289440
    Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289438
    Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9271989
    Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 1, 2016
    Assignee: CMPD LICENSING, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge
  • Patent number: 9140703
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: September 22, 2015
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9056139
    Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: June 16, 2015
    Assignee: KEAN UNIVERSITY
    Inventor: Evros Vassiliou
  • Publication number: 20150139973
    Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
  • Publication number: 20150125525
    Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.
    Type: Application
    Filed: April 29, 2013
    Publication date: May 7, 2015
    Applicant: TILLOTTS PHARMA AG
    Inventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Goutte, Abdul Waseh Basit, Felipe Jose, Oliveira Varum, Ana Cristina Freire
  • Patent number: 9023369
    Abstract: The invention relates to freeze-dried molded articles, containing ?50% by wt. of one or more active substances, and ?15% by wt. of one or more scaffold-forming agents, with proteins being excepted, as well as optionally one or more auxiliary substances, in each case based on the total composition of the freeze-dried molded article, whose 1% by wt. solution or suspension in water, at 20° C., has a pH value <7. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: May 5, 2015
    Inventors: Ralf Malessa, Claudia Elsinghorst, Fabian Kuhlmann, Uwe Wagner
  • Publication number: 20150118303
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: November 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9018193
    Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Bev-Rx, Inc.
    Inventor: Kyle A. Reed
  • Patent number: 8999961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 7, 2015
    Assignees: Purdue Pharma, L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150080353
    Abstract: The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 19, 2015
    Inventors: Mewa SINGH, Maninder SANDHU